Mawer Investment Management
BIO icon

Mawer Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mawer Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Sell
71,577
-117,207
-62% -$33.2M 0.14% 85
2026
Q1 		$52.6M Sell
188,784
-45,162
-19% -$13M 0.34% 64
2025
Q4 		$70.9M Sell
233,946
-9,522
-4% -$2.97M 0.4% 55
2025
Q3 		$68.3M Sell
243,468
-23,640
-9% -$6.43M 0.35% 59
2025
Q2 		$64.5M Sell
267,108
-27,771
-9% -$6.56M 0.33% 61
2025
Q1 		$71.8M Buy
294,879
+37,952
+15% +$11.4M 0.35% 60
2024
Q4 		$84.4M Buy
256,927
+39,042
+18% +$13.3M 0.38% 55
2024
Q3 		$72.9M Buy
217,885
+84,237
+63% +$26.8M 0.33% 54
2024
Q2 		$36.5M Buy
133,648
+295
+0.2% +$85.8K 0.17% 70
2024
Q1 		$46.1M Buy
133,353
+9,475
+8% +$3.12M 0.21% 67
2023
Q4 		$40M Sell
123,878
-38,954
-24% -$12.2M 0.2% 69
2023
Q3 		$58.4M Buy
162,832
+21,808
+15% +$8.41M 0.31% 59
2023
Q2 		$53.5M Buy
141,024
+43,880
+45% +$17.9M 0.28% 66
2023
Q1 		$46.5M Buy
97,144
+8,574
+10% +$4.01M 0.25% 69
2022
Q4 		$37.2M Buy
88,570
+18,710
+27% +$7.55M 0.21% 71
2022
Q3 		$29.1M Buy
69,860
+2,150
+3% +$1.07M 0.18% 73
2022
Q2 		$33.5M Buy
67,710
+27,010
+66% +$14.1M 0.19% 72
2022
Q1 		$22.9M Buy
40,700
+110
+0.3% +$66.3K 0.11% 79
2021
Q4 		$30.7M Buy
40,590
+218
+0.5% +$163K 0.14% 85
2021
Q3 		$30.1M Sell
40,372
-14
-0% -$10.5K 0.14% 85
2021
Q2 		$26M Buy
40,386
+52
+0.1% +$31.6K 0.13% 84
2021
Q1 		$23M Buy
40,334
+8,213
+26% +$4.86M 0.13% 83
2020
Q4 		$18.7M Buy
+32,121
New +$18.3M 0.11% 80

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Mawer Investment Management's BIO Position: Q2 2026 in Review

Mawer Investment Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 62% in Q2 2026, selling an estimated $33.2M and leaving 71,577 shares worth $21M. The position accounts for 0.14% of the portfolio, ranked #85.

Mawer Investment Management first reported a position in BIO in Q4 2020 and has held it in 23 quarters since. The position peaked at $84.4M in Q4 2024. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Mawer Investment Management held 71,577 shares of Bio-Rad Laboratories Class A worth $21M as of Q2 2026.
  • Mawer Investment Management sold 117,207 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $33.2M.
  • Bio-Rad Laboratories Class A made up 0.14% of Mawer Investment Management's portfolio in Q2 2026, its #85 holding.
  • Mawer Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and has held it in 23 quarters since.
  • Mawer Investment Management's Bio-Rad Laboratories Class A position peaked at $84.4M in Q4 2024.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Mawer Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.